Abstract: J AM ACAD DERMATOL
VOLUME 84, NUMBER 6
Medicine, Boston University School of Medicine,
Massachusetts.e
Drs Hartman and La are cofirst authors.
Funding sources: Supported by an American Skin
Association research grant (120795 to Dr
Hartman).
IRB approval status: Not applicable.
Reprints not available from the authors.
Correspondence to: Rebecca I. Hartman, MD, MPH,
Harvard Medical School, BWH Department of
Dermatology, 221 Longwood Ave, Boston, MA
02215
E-mail: rhartman@bwh.harvard.edu
Conflicts of interest
None disclosed.
REFERENCES
1. Faries MB, Thompson JF, Cochran AJ, et al. Completion
dissection or observation for sentinel-node metastasis in
melanoma. N Engl J Med. 2017;376(23):2211-2222.
2. Wei EX, Chen L, Ma F, Keri J, Hu S. Recent dermatology visit is
associated with thinner Breslow depth nodular melanomas.
J Am Acad Dermatol. 2019;80(4):1143-1144.
3. Roetzheim RG, Lee JH, Ferrante JM, et al. The influence of
dermatologist and primary care physician visits on melanoma
outcomes among Medicare beneficiaries. J Am Board Fam
Med. 2013;26(6):637-647.
4. Jackson GL, Melton LD, Abbott DH, et al. Quality of
nonmetastatic colorectal cancer care in the Department of
Veterans Affairs. J Clin Oncol. 2010;28(19):3176-3181.
5. Orkaby AR, Nussbaum L, Ho YL, et al. The burden of frailty
among U.S. veterans and its association with mortality,
2002-2012. J Gerontol A Biol Sci Med Sci. 2019;74(8):
1257-1264.
https://doi.org/10.1016/j.jaad.2020.12.069
Chronic hydroxychloroquine
therapy and COVID-19 outcomes: A
retrospective case-control analysis
To the Editor: Hydroxychloroquine (HCQ) has failed
to show significant therapeutic benefit for patients
with coronavirus disease-2019 (COVID-19) in recent
studies, although interest in this medication’s
potential pre- and postprophylactic efficacy remains,
with 1 retrospective study showing reduced
COVID-19 infection among patients taking chronic
HCQ.1,2 In this study, we sought to evaluate
COVID-19 clinical outcomes in patients taking
chronic HCQ for an underlying condition as well as
in a matched cohort not taking HCQ at time of
COVID-19 diagnosis.
Research Letters 1769
Table I. Hydroxychloroquine indication, dosage,
and duration at time of COVID-19 diagnosis
HCQ indication, dosage, and duration (N = 50)
HCQ indication
Systemic lupus erythematosus
Rheumatoid arthritis
Connective tissue disease
overlap syndromes
€gren syndrome
Sjo
Mixed connective tissue disease
Undifferentiated connective
tissue disease
Erythema nodosum during
pregnancy
Carcinoid
Myalgic encephalomyelitis/
chronic fatigue syndrome
Acquired hypogammaglobulinemia
HCQ dosage
200 mg HCQ daily
200 mg HCQ 2 times daily
(400 mg total)
200 mg HCQ 3 times daily
(600 mg total)
Mean duration of HCQ therapy
before COVID-19 diagnosis (IQR)
n (%)
17 (34.0)
11 (22.0)
9 (18.0)
6 (12.0)
2 (4.0)
1 (2.0)
1 (2.0)
1 (2.0)
1 (2.0)
1 (2.0)
13 (36.0)
36 (72.0)
1 (2.0)
28 (14.25-44.25)
months
COVID-19, Coronavirus disease-2019; HCQ, hydroxychloroquine;
IQR, interquartile range.
We identified all patients with severe acute
respiratory syndrome coronavirus 2 seen at New
York University from March to April 2020 using
International Classification of Diseases, 10th
revision codes and included patients taking HCQ
for $6 weeks before their COVID-19 diagnosis.
Control subjects were randomly selected from the
remaining severe acute respiratory syndrome
coronavirus 2epositive patients with automated
matching for age, gender, and immunosuppressive
medication using..
DOI record:
{
"DOI": "10.1016/j.jaad.2020.10.098",
"ISSN": [
"0190-9622"
],
"URL": "http://dx.doi.org/10.1016/j.jaad.2020.10.098",
"alternative-id": [
"S0190962221001109"
],
"assertion": [
{
"label": "This article is maintained by",
"name": "publisher",
"value": "Elsevier"
},
{
"label": "Article Title",
"name": "articletitle",
"value": "Chronic hydroxychloroquine therapy and COVID-19 outcomes: A retrospective case-control analysis"
},
{
"label": "Journal Title",
"name": "journaltitle",
"value": "Journal of the American Academy of Dermatology"
},
{
"label": "CrossRef DOI link to publisher maintained version",
"name": "articlelink",
"value": "https://doi.org/10.1016/j.jaad.2020.10.098"
},
{
"label": "Content Type",
"name": "content_type",
"value": "article"
},
{
"label": "Copyright",
"name": "copyright",
"value": "© 2021 Published by Elsevier on behalf of the American Academy of Dermatology, Inc."
}
],
"author": [
{
"affiliation": [],
"family": "Rangel",
"given": "Lauren K.",
"sequence": "first"
},
{
"affiliation": [],
"family": "Shah",
"given": "Payal",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Lo Sicco",
"given": "Kristen",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Caplan",
"given": "Avrom S.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Femia",
"given": "Alisa",
"sequence": "additional"
}
],
"container-title": "Journal of the American Academy of Dermatology",
"container-title-short": "Journal of the American Academy of Dermatology",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"clinicalkey.fr",
"jaad.org",
"clinicalkey.jp",
"clinicalkey.es",
"clinicalkey.com.au",
"clinicalkey.com",
"elsevier.com",
"sciencedirect.com"
]
},
"created": {
"date-parts": [
[
2021,
1,
11
]
],
"date-time": "2021-01-11T08:52:06Z",
"timestamp": 1610355126000
},
"deposited": {
"date-parts": [
[
2024,
4,
4
]
],
"date-time": "2024-04-04T19:54:07Z",
"timestamp": 1712260447000
},
"indexed": {
"date-parts": [
[
2024,
4,
5
]
],
"date-time": "2024-04-05T05:11:03Z",
"timestamp": 1712293863453
},
"is-referenced-by-count": 0,
"issue": "6",
"issued": {
"date-parts": [
[
2021,
6
]
]
},
"journal-issue": {
"issue": "6",
"published-print": {
"date-parts": [
[
2021,
6
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2021,
6,
1
]
],
"date-time": "2021-06-01T00:00:00Z",
"timestamp": 1622505600000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S0190962221001109?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S0190962221001109?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"page": "1769-1772",
"prefix": "10.1016",
"published": {
"date-parts": [
[
2021,
6
]
]
},
"published-print": {
"date-parts": [
[
2021,
6
]
]
},
"publisher": "Elsevier BV",
"reference": [
{
"DOI": "10.1007/s11606-020-06146-w",
"article-title": "Chloroquine and hydroxychloroquine for the treatment of COVID-19: a systematic review and meta-analysis",
"author": "Elavarasi",
"doi-asserted-by": "crossref",
"first-page": "3308",
"journal-title": "J Gen Intern Med",
"key": "10.1016/j.jaad.2020.10.098_bib1",
"volume": "35",
"year": "2020"
},
{
"DOI": "10.1002/jmv.26286",
"article-title": "Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection",
"author": "Ferreira",
"doi-asserted-by": "crossref",
"first-page": "755",
"journal-title": "J Med Virol",
"key": "10.1016/j.jaad.2020.10.098_bib2",
"volume": "93",
"year": "2021"
},
{
"DOI": "10.1056/NEJMoa2016638",
"article-title": "A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19",
"author": "Boulware",
"doi-asserted-by": "crossref",
"first-page": "517",
"journal-title": "N Engl J Med",
"key": "10.1016/j.jaad.2020.10.098_bib3",
"volume": "383",
"year": "2020"
},
{
"DOI": "10.1080/08916930500285352",
"article-title": "Infections and SLE",
"author": "Zandman-Goddard",
"doi-asserted-by": "crossref",
"first-page": "473",
"journal-title": "Autoimmunity",
"key": "10.1016/j.jaad.2020.10.098_bib4",
"volume": "38",
"year": "2005"
},
{
"DOI": "10.1002/cpt.1874",
"article-title": "Finding the dose for hydroxychloroquine prophylaxis for COVID-19: the desperate search for effectiveness",
"author": "Al-Kofahi",
"doi-asserted-by": "crossref",
"first-page": "766",
"journal-title": "Clin Pharmacol Ther",
"key": "10.1016/j.jaad.2020.10.098_bib5",
"volume": "108",
"year": "2020"
}
],
"reference-count": 5,
"references-count": 5,
"relation": {},
"resource": {
"primary": {
"URL": "https://linkinghub.elsevier.com/retrieve/pii/S0190962221001109"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Dermatology"
],
"subtitle": [],
"title": "Chronic hydroxychloroquine therapy and COVID-19 outcomes: A retrospective case-control analysis",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy",
"volume": "84"
}
